Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Injectable insulin

Peptide · Agonist of insulin receptor (INSR) · developed by Eli Lilly and Company

Phase 3 Most advanced trial (none active)
1 Registered trials

What is Injectable insulin?

Injectable insulin is a peptide hormone given by injection, studied in patients with type 2 diabetes mellitus at a patient-specific dose before meals.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Peptide
Targets
insulin receptor (INSR)
Mechanism
Agonist of insulin receptor (INSR)
Therapy area
Endocrine, Metabolic
Developer
Eli Lilly and Company
In trials of
ALKS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00325364 Phase 3 Diabetes Mellitus, Type 2 Completed ALKS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 2

Other drugs acting on INSR

Insulin Degludec FDA approved Insulin Glargine FDA approved Insulin Lispro FDA approved Injected insulin Phase 3 ORMD-0801 Phase 3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.